Auffarth Gerd 4
4 · Outlook Therapeutics, Inc. · Filed Oct 5, 2020
Insider Transaction Report
Form 4
Auffarth Gerd
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-10-05$0.51/sh+85,586$44,000→ 85,586 totalExercise: $0.71Exp: 2030-10-05→ Common Stock (85,586 underlying)
Footnotes (1)
- [F1]The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.